Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, on Wednesday said the post-marketing surveillance (PMS) study on Favipiravir (FabiFlu) has been concluded. The study was conducted in over 1,000 patients of COVID-19, for which the results showed no new safety signals or concerns with the use of Favipiravir, and already-known side effects such as weakness, gastritis, diarrhoea, vomiting etc., were found to be mild in nature. The time for fever resolution was 4 days, while time for clinical cure was 7 days.from IndiaTV India: Google News Feed https://ift.tt/3Edm6aJ
via
No comments:
Post a Comment
Please do not enter spam link in the comment box. Suggestions are invited for improvement.